For the Inventor, By the Inventor

Enter assignee name

Tarrytown, NY, United States of America

Regeneran Pharmaceuticals, Inc.

USPTO Granted Patents = 49

Forward Citations = 92

Loading Chart...

Loading Chart...

151 inventors (with patents filed for the assignee):

Andrew J Murphy (12 out of 349 patents)

Lynn Macdonald (8 out of 180 patents)

Shunhai Wang (6 out of 58 patents)

4. Eric L Smith (6 out of 85 patents)

5. Ning Li (5 out of 53 patents)

6. Sean Stevens (4 out of 158 patents)

7. Brian Zambrowicz (4 out of 19 patents)

8. Ka-Man Venus Lai (4 out of 54 patents)

9. John R McWhirter (4 out of 75 patents)

10. Andrew Tustian (3 out of 19 patents)

11. Frank Delfino (3 out of 25 patents)

12. Amy S Johnson (3 out of 23 patents)

13. Jessica Kirshner (3 out of 29 patents)

14. Nicholas J Papadopoulos (3 out of 92 patents)

15. Shawn M Lawrence (3 out of 25 patents)

Core Competencies:

Chromatography

Zinc Inhibitors

Genetic Modification

Nuclease-Mediated Expansion

Humanized Genes

IL10 Agonists

Antibody-Drug Conjugates

CRISPR/Cas Systems

Bispecific Antibodies

Raman Spectroscopy

Monoclonal Antibodies

Immunoglobulin Sequences

49 patents: Sort by Forward Citations

1. 11717586 - Compositions and methods for reducing bioburden in chromatography (2023-08-08),

2. 11713922 - Target residual moisture content for lyophilized drug product (2023-08-01),

3. 11713461 - Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors (2023-08-01),

4. 11697828 - Methods and compositions for targeted genetic modification using paired guide RNAs (2023-07-11),

5. 11690362 - Nuclease-mediated repeat expansion (2023-07-04),

6. 11684050 - Non-human animals having a humanized programmed cell death 1 gene (2023-06-27),

7. 11674968 - Methods for identifying free thiols in proteins (2023-06-13),

8. 11673930 - IL10 agonists and methods of use thereof (2023-06-13),

9. 11666658 - Rifamycin analogs and antibody-drug conjugates thereof (2023-06-06),

10. 11642390 - Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody (2023-05-09),

11. 11622547 - Genetically modified mouse that expresses human albumin (2023-04-11),

12. 11589562 - Mouse model of DITRA disease and uses thereof (2023-02-28),

13. 11584966 - Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof (2023-02-21),

14. 11559576 - Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof (2023-01-24),

15. 11519004 - Transcription modulation in animals using CRISPR/Cas systems (2022-12-06),

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron's innovative approach to drug discovery and development has led to multiple FDA-approved therapies and a robust pipeline of new products in development. The company is constantly pushing the boundaries of science to deliver life-changing medicines to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

49 Patents

#5 in Tarrytown, NY

#395 in New York

#6,913 in US

#13,866 in the World

Tarrytown, NY, United States of America

Regeneran Pharmaceuticals, Inc.

Forward Citations = 92

151 inventors:

Andrew J Murphy (12 out of 349 patents)

Lynn Macdonald (8 out of 180 patents)

Shunhai Wang (6 out of 58 patents)

4. Eric L Smith (6 out of 85 patents)

5. Ning Li (5 out of 53 patents)

Please report any incorrect information to support@idiyas.com

Loading…